Analytical Comparison of Infliximab and Related Biosimilars

Authors

  • Maria-Christina S. Malinao Phenomenex Inc., 411 Madrid Avenue, Torrance, CA 90501 USA
  • Morgen Kramer Phenomenex Inc., 411 Madrid Avenue, Torrance, CA 90501 USA
  • Chad Elchman Phenomenex Inc., 411 Madrid Avenue, Torrance, CA 90501 USA
  • Brian Rivera Phenomenex Inc., 411 Madrid Avenue, Torrance, CA 90501 USA
  • Sean Orlowicz Phenomenex Inc., 411 Madrid Avenue, Torrance, CA 90501 USA
  • Helko Behr Phenomenex Ltd., Zeppelinstr. 5, 63741 Aschaffenburg, Germany

DOI:

https://doi.org/10.33892/aph.2021.91.184

Keywords:

infliximab, biosimilar, analytics

Published

2021-11-15

How to Cite

(1)
Malinao, M.-C. S.; Kramer, M.; Elchman, C.; Rivera, B.; Orlowicz, S.; Behr, H. Analytical Comparison of Infliximab and Related Biosimilars. Acta Pharm Hung 2021, 91, 184.

Issue

Vol. 91 No. 3-4 (2021): Abstracts of DDRS 2021 Conference, November 15-17, 2021, Budapest, Hungary

Section

Short communication

Copyright (c) 2021 Acta Pharmaceutica Hungarica

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

APH is published as a diamond open-access journal under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Creative Commons License